ZL-1310 Clinical Trials (2026): 4 Studies for SCLC & Small-cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 ZL-1310 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including SCLC & Small-cell Lung Cancer) and 1,145 total planned enrollment. 1 Phase 3 ZL-1310 trial are listed. 4 ZL-1310 clinical trials are actively recruiting at 66 U.S. sites across 21 states. Most recent activity: NCT07531095 (May 2031).
Where to Participate: All ZL-1310 Trial Sites in the U.S. (66 sites across 21 states)
Every actively recruiting ZL-1310trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | City of Hope Cancer Center Phoenix | Goodyear85338 | NCT07531095 | Map |
| CA | University of California San Diego | La Jolla92093 | NCT07218146 | Map |
| CA | UC Davis Comprehensive Cancer Center | Sacramento95817 | NCT07218146 | Map |
| CA | University of California San Francisco/Helen Diller Family Comprehensive Cancer Center | San Francisco94143 | NCT06885281 | Map |
| CO | University of Colorado | Aurora80045 | NCT07218146 | Map |
| CT | Yale Cancer Center | New Haven06519 | NCT06179069 | Map |
| CT | Yale Cancer Center/Clinical Trials Office | New Haven06519 | NCT07218146 | Map |
| FL | Clermont Oncology Center | Clermont34711 | NCT07218146 | Map |
| FL | Mid Florida Hematology and Oncology Center | Orange City32763 | NCT07218146 | Map |
| FL | Cancer Centers of Bevard | Rockledge32955 | NCT07218146 | Map |
| FL | Sarah Cannon Research Institute | Sarasota34232 | NCT06179069 | Map |
| FL | Sarah Cannon Research Institute | Sarasota34232 | NCT07218146 | Map |
| FL | Florida Cancer Specialists - North | St. Petersburg33701-4553 | NCT07218146 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07531095 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07218146 | Map |
| FL | Florida Cancer Specialists - East | West Palm Beach33401 | NCT07218146 | Map |
| IL | Illinois Cancer Care | Peoria61615 | NCT07218146 | Map |
| IL | OSF St. Francis Medical Center | Peoria61637 | NCT06885281 | Map |
| IL | OSF St. Francis Medical Center | Peoria61637 | NCT07218146 | Map |
| IL | City of Hope Chicago | Zion60099 | NCT07531095 | Map |
| IA | University of Iowa | Iowa City52242 | NCT07218146 | Map |
| IA | University of Iowa Mission Health Cancer + Blood | Waukee50263 | NCT07218146 | Map |
| KY | Norton Cancer Institute | Louisville40202 | NCT07218146 | Map |
| MD | American Oncology Partners, PA - The Center for Cancer and Blood Disorders | Bethesda20817 | NCT07218146 | Map |
| MD | Maryland Oncology Hematology | Silver Spring20904 | NCT07218146 | Map |
| MI | Barbara Ann Karmanos Cancer Institute | Detroit48201 | NCT06179069 | Map |
| MI | Henry Ford Health Cancer | Detroit48202 | NCT07218146 | Map |
| MI | Karmanos Cancer Center | Detroit48201 | NCT06885281 | Map |
| MN | Health Partners Cancer Center at Regions Hospital | Saint Paul55101 | NCT07531095 | Map |
| MO | Missouri Cancer Associates | Columbia65201 | NCT07218146 | Map |
| MO | Mercy South | St Louis63128 | NCT07218146 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06179069 | Map |
| NY | Roswell Park Comprehensive Cancer Center | Buffalo14263 | NCT06179069 | Map |
| NY | Memorial Sloan-Kettering Cancer Center | New York10065 | NCT06885281 | Map |
| NY | New York University Cancer Institute | New York10016 | NCT07531095 | Map |
| NY | Stony Brook Cancer Center | Stony Brook11794-7007 | NCT07218146 | Map |
| NY | Montefiore Medical Center | The Bronx10461 | NCT07218146 | Map |
| NC | Duke University | Durham27710 | NCT06179069 | Map |
| OH | Cleveland Clinic - Akron General Medical Center | Akron44302 | NCT07218146 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT07218146 | Map |
| OH | Cleveland Clinic - Fairview Hospital Molly Pavilion | Cleveland44111 | NCT07218146 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06885281 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06179069 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT07218146 | Map |
| OH | Cleveland Clinic - Hillcrest Hospital Cancer Center | Mayfield Heights44124 | NCT07218146 | Map |
| PA | Consultants in Medical Oncology and Hematology | Broomall19008 | NCT07218146 | Map |
| PA | Alliance Cancer Specialists | Media19063 | NCT07218146 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06885281 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT07218146 | Map |
| PA | University of Pittsburgh (UPMC) Hillman Cancer Center | Pittsburgh15232 | NCT07218146 | Map |
| PA | University of Pittsburgh Hillman Cancer Center | Pittsburgh15232 | NCT06179069 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06179069 | Map |
| TN | Baptist Cancer Center | Memphis38120 | NCT07531095 | Map |
| TN | SCRI OP (Oncology Partners) | Nashville37203 | NCT06885281 | Map |
| TN | SCRI OP (Oncology Partners) | Nashville37203 | NCT07218146 | Map |
| TX | Texas Oncology - Central South | Austin78745 | NCT07218146 | Map |
| TX | Texas Oncology / Sammons Cancer Center | Dallas75246 | NCT06885281 | Map |
| TX | University of Texas Southwestern Medical Center/Clinical Research Department | Dallas75390-9020 | NCT07218146 | Map |
| TX | The University of Texas M. D. Anderson Cancer Center | Houston77030 | NCT06885281 | Map |
| TX | Texas Oncology - Central South | McAllen78503 | NCT06885281 | Map |
| TX | Texas Oncology - West Texas | Odessa79761 | NCT07218146 | Map |
| VA | Next Virginia | Fairfax22031 | NCT07531095 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT06179069 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT06885281 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT07218146 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT06885281 | Map |
ZL-1310 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 2 | 2 |
| P1/P2 | 1 | 1 |
| P3 | 1 | 1 |
Recruiting ZL-1310 clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07531095 | DeLLphi-313Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | P1 | Small Cell Lung Cancer | 160 | Apr 2026 |
| NCT07218146 | DLLEVATEA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | P3 | Small-cell Lung Cancer | 480 | Nov 2025 |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | P1/P2 | Solid Tumors | 166 | May 2025 |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | P1 | SCLC | 339 | Jan 2024 |
ZL-1310 clinical trials by indication
Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07531095 | DeLLphi-313 | P1 | recruiting | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) |
Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07218146 | DLLEVATE | P3 | recruiting | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06885281 | — | P1/P2 | recruiting | A Study of ZL-1310 in Participants With Selected Solid Tumors |
SCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06179069 | — | P1 | recruiting | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer |
ZL-1310 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| DLLEVATE | NCT07218146 | P3 | recruiting | Small-cell Lung Cancer | 480 | — |
All ZL-1310 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07531095 | DeLLphi-313 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | P1 | recruiting | 160 | Amgen | Apr 2026 |
| NCT07218146 | DLLEVATE | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | P3 | recruiting | 480 | Zai Lab (Shanghai) Co., Ltd. | Nov 2025 |
| NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | P1/P2 | recruiting | 166 | Zai Lab (Shanghai) Co., Ltd. | May 2025 | |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | P1 | recruiting | 339 | Zai Lab (Shanghai) Co., Ltd. | Jan 2024 |
ZL-1310 clinical trials: frequently asked questions
- How many ZL-1310 clinical trials are there?
- 4 ZL-1310 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants.
- Are ZL-1310 clinical trials recruiting in 2026?
- Yes — 4 ZL-1310 trials are actively recruiting in 2026, with 66 U.S. sites across 21 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ZL-1310 being studied for?
- ZL-1310 is being studied for SCLC, Small-cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors. The trials are grouped by indication on this page.
- What phase is ZL-1310 in?
- ZL-1310 clinical trials span 1 Phase 3, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ZL-1310 clinical trials?
- The lead sponsor across the most ZL-1310 trials is Zai Lab (Shanghai) Co., Ltd., with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ZL-1310as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: